Improving Therapeutic Outcomes in Heart Failure with Reduced Nonvalvular Ejection Fraction: A Clinical Study of Heart Failure Education Intervention

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Apr 29

PMID 38682726

Authors

Xueli Tian

Xiaozeng Li

Qingqing Zhang

Xiangling Qiao

Xin Li

Zijian Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: The current study delves into the impact of heart failure education intervention on improving therapeutic outcomes for heart failure (HF) patients with reduced nonvalvular ejection fraction.

Methods: There involved a total of 60 HF patients with non-valvular ejection fraction reduction who met the inclusion requirements. Patients enrolled were randomly distributed into an observation group and a control group. The observation group received heart failure education intervention, while the control group received conventional intervention. The therapeutic effect, changes in physical indicators, cardiac function indicators, coagulation function, self-management scale scores, and the incidence of adverse cardiovascular events were meticulously evaluated.

Results: The total effective proportion in the observation group was 96.67%, which was significantly higher than the control group's proportion of 76.67% (p < .05). After treatment, several parameters in the observation group showed significant improvements compared to the control group: hs-CRP, IL-6, LVEDV value, LVESV value, PT value, APTT value, and TT value were all evidently lower in the observation group. Additionally, the cardiac index, LVEF value, and heart failure self-management scale fraction were significantly higher in the observation group compared to the control group (p < .05). Furthermore, the incidence of adverse cardiovascular events in the observation group was only 6.67%, which was significantly lower than the control group's incidence of 20.00% (p < .05).

Conclusion: Heart failure education intervention demonstrates effectiveness in improving the therapeutic outcomes for HF patients and reduced nonvalvular ejection fraction. Additionally, it enhances patients' self-management abilities. Given these positive results, it is highly recommended to promote and implement HF education intervention in clinical practice.

Citing Articles

Improving therapeutic outcomes in heart failure with reduced nonvalvular ejection fraction: A clinical study of heart failure education intervention.

Tian X, Li X, Zhang Q, Qiao X, Li X, Zhang Z Clin Cardiol. 2024; 47(5):e24265.

PMID: 38682726 PMC: 11057052. DOI: 10.1002/clc.24265.

References

Guazzi M, Wilhelm M, Halle M, Van Craenenbroeck E, Kemps H, de Boer R . Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy - A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of.... Eur J Heart Fail. 2022; 24(8):1327-1345. PMC: 9542249. DOI: 10.1002/ejhf.2601. View

Baldewijns K, Boyne J, Rohde C, De Maesschalck L, Deville A, Brandenburg V . What kind of patient education and self-care support do patients with heart failure receive, and by whom? Implementation of the ESC guidelines for heart failure in three European regions. Heart Lung. 2022; 57:25-30. DOI: 10.1016/j.hrtlng.2022.07.013. View

Siennicka A, Biegus J, Gajewski P, Mlynarska K, Sokolski M, Siwolowski P . A Pilot Study on Standardized In-hospital Education About Heart Failure Conducted During the First Days After Decompensation. Crit Pathw Cardiol. 2023; 22(1):13-18. DOI: 10.1097/HPC.0000000000000313. View

Nagatomi Y, Ide T, Higuchi T, Nezu T, Fujino T, Tohyama T . Home-based cardiac rehabilitation using information and communication technology for heart failure patients with frailty. ESC Heart Fail. 2022; 9(4):2407-2418. PMC: 9288767. DOI: 10.1002/ehf2.13934. View

Tsai W, Hsu S, Chiu Y, Yang J, Pai M, Ko M . Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2022; 12(10):e060655. PMC: 9577928. DOI: 10.1136/bmjopen-2021-060655. View

Inzucchi S, Claggett B, Vaduganathan M, Desai A, Jhund P, de Boer R . Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised,.... Lancet Diabetes Endocrinol. 2022; 10(12):869-881. DOI: 10.1016/S2213-8587(22)00308-4. View

Martens P, Dauw J, Verbrugge F, Nijst P, Meekers E, Augusto Jr S . Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial. Circulation. 2022; 147(3):201-211. DOI: 10.1161/CIRCULATIONAHA.122.062486. View

Peikert A, Martinez F, Vaduganathan M, Claggett B, Kulac I, Desai A . Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial. Circ Heart Fail. 2022; 15(10):e010080. DOI: 10.1161/CIRCHEARTFAILURE.122.010080. View

Cvijic M, Rib Y, Danojevic S, Radulescu C, Nazghaidze N, Vardas P . Heart failure with mildly reduced ejection fraction: from diagnosis to treatment. Gaps and dilemmas in current clinical practice. Heart Fail Rev. 2022; 28(4):767-780. DOI: 10.1007/s10741-022-10267-1. View

10.

Filippatos G, Anker S, Butler J, Farmakis D, Ferreira J, Gollop N . Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR-Reduced. Eur J Heart Fail. 2022; 24(12):2297-2304. PMC: 10092219. DOI: 10.1002/ejhf.2707. View

11.

Monda V, Gentile S, Porcellati F, Satta E, Fucili A, Monesi M . Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes. Adv Ther. 2022; 39(11):4837-4846. PMC: 9525351. DOI: 10.1007/s12325-022-02310-2. View

12.

Kosiborod M, Angermann C, Collins S, Teerlink J, Ponikowski P, Biegus J . Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation. 2022; 146(4):279-288. PMC: 9311476. DOI: 10.1161/CIRCULATIONAHA.122.059725. View

13.

Lin Y, Cai Z, Yuan J, Liu H, Pang X, Chen Q . Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction: an updated systematic review and network meta-analysis of randomized controlled trials. Cardiovasc Diabetol. 2022; 21(1):237. PMC: 9644566. DOI: 10.1186/s12933-022-01679-2. View

14.

Diez-Villanueva P, Jimenez-Mendez C, Perez A, Esteban-Fernandez A, Datino T, Martinez-Selles M . Do Elderly Patients with Heart Failure and Reduced Ejection Fraction Benefit from Pharmacological Strategies for Prevention of Arrhythmic Events?. Cardiology. 2023; 148(3):195-206. DOI: 10.1159/000530424. View

15.

Oliver B, Travis A, Hughes E, Condrat L, Ullman J, Cohen B . Improved 30-Day Heart Failure Readmissions Following Implementation of an Advanced Cardiovascular Education (ACE) Academy. J Nurs Care Qual. 2022; 37(4):300-306. DOI: 10.1097/NCQ.0000000000000631. View

16.

Reddy Y, Borlaug B, Gersh B . Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation. 2022; 146(4):339-357. DOI: 10.1161/CIRCULATIONAHA.122.057444. View

17.

Kosiborod M, Bhatt A, Claggett B, Vaduganathan M, Kulac I, Lam C . Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2022; 81(5):460-473. DOI: 10.1016/j.jacc.2022.11.006. View

18.

Ledwidge M, Dodd J, Ryan F, Sweeney C, McDonald K, Fox R . Effect of Sacubitril/Valsartan vs Valsartan on Left Atrial Volume in Patients With Pre-Heart Failure With Preserved Ejection Fraction: The PARABLE Randomized Clinical Trial. JAMA Cardiol. 2023; 8(4):366-375. PMC: 9996460. DOI: 10.1001/jamacardio.2023.0065. View

19.

Clements L, Frazier S, Lennie T, Chung M, Moser D . Improvement in Heart Failure Self-Care and Patient Readmissions with Caregiver Education: A Randomized Controlled Trial. West J Nurs Res. 2022; 45(5):402-415. DOI: 10.1177/01939459221141296. View

20.

Abudureyimu M, Luo X, Wang X, Sowers J, Wang W, Ge J . Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. J Mol Cell Biol. 2022; 14(5). PMC: 9465638. DOI: 10.1093/jmcb/mjac028. View